Ciprofloxacin and ursodeoxycholic acid tab Ofloxacin and Ornidazole
Reading Document
Medical Text Search
Ciprofloxacin ursodeoxycholic acid combination tablet uses indications
Medical Text Search
Ofloxacin Ornidazole combination tablet uses indications pharmacology
GradeResponse
GradeResponse
The database didn't return targeted results for these combinations. Here is a comprehensive answer based on pharmacological knowledge:
Drug Combination Profiles
1. Ciprofloxacin + Ursodeoxycholic Acid (UDCA)
Overview
This is a combination used in hepatobiliary infections, particularly cholangitis and biliary tract infections.
Individual Components
| Component | Class | Mechanism |
|---|---|---|
| Ciprofloxacin | Fluoroquinolone antibiotic | Inhibits bacterial DNA gyrase and topoisomerase IV → bactericidal |
| Ursodeoxycholic Acid (UDCA) | Bile acid | Replaces hydrophobic toxic bile acids, improves bile flow (choleretic), hepatoprotective, immunomodulatory |
Rationale for Combination
- Ciprofloxacin achieves high biliary concentration, making it ideal for treating gram-negative infections of the biliary tract
- UDCA improves bile flow and reduces cholestasis, creating a less hostile biliary environment; also has direct cytoprotective effects on hepatocytes and cholangiocytes
- The combination addresses both the infectious and cholestatic components of biliary disease simultaneously
Indications
- Cholangitis (ascending or recurrent)
- Biliary tract infections with cholestasis
- Primary sclerosing cholangitis (PSC) with superimposed infection
- Post-ERCP cholangitis prophylaxis/treatment
- Biliary infections in patients with choledocholithiasis
Dosing (Typical)
- Ciprofloxacin: 250–500 mg per tablet component
- UDCA: 150–300 mg per tablet component
- Usually given twice daily with or after food
Pharmacokinetics
- Ciprofloxacin: Good oral bioavailability (~70%), excellent biliary excretion
- UDCA: Absorbed in small intestine, undergoes enterohepatic circulation, concentrates in bile
Adverse Effects
| Drug | Key Adverse Effects |
|---|---|
| Ciprofloxacin | Nausea, tendinopathy, QTc prolongation, photosensitivity, C. difficile risk |
| UDCA | Generally well tolerated; diarrhea, pruritus (rare); may worsen advanced cirrhosis |
Contraindications
- Ciprofloxacin: Hypersensitivity, concurrent use with tizanidine, children (relative)
- UDCA: Acute cholecystitis, biliary obstruction, inflammatory bowel disease (relative)
- Interaction: Antacids reduce ciprofloxacin absorption — separate by 2 hours
2. Ofloxacin + Ornidazole
Overview
A very widely used broad-spectrum anti-infective combination, popular in gastroenterology and gynecology, particularly in South/Southeast Asia.
Individual Components
| Component | Class | Mechanism |
|---|---|---|
| Ofloxacin | Second-generation fluoroquinolone | Inhibits DNA gyrase + topoisomerase IV → bactericidal against gram-negative and gram-positive organisms |
| Ornidazole | Nitroimidazole (5-nitroimidazole) | Enters anaerobes/protozoa → reduced to toxic nitro radical → DNA strand breakage → antiprotozoal + anti-anaerobic |
Rationale for Combination
- Ofloxacin covers aerobic gram-negative and gram-positive bacteria
- Ornidazole covers anaerobes and protozoa (Entamoeba, Giardia, Trichomonas)
- Together they provide comprehensive polymicrobial coverage for mixed infections
Indications
- Acute infectious diarrhea / gastroenteritis (bacterial + amoebic)
- Amoebic dysentery and amoebic liver abscess
- Giardiasis
- Pelvic inflammatory disease (PID)
- Trichomoniasis
- Intra-abdominal infections
- Surgical prophylaxis (colorectal, gynecological)
- H. pylori eradication (as part of triple therapy, less common now)
Standard Formulation & Dosing
- Ofloxacin 200 mg + Ornidazole 500 mg — standard tablet
- Adult dose: 1 tablet twice daily × 5–7 days (varies by indication)
- Taken with food to reduce GI side effects
Spectrum of Coverage
| Organism Type | Covered By |
|---|---|
| Gram-negative aerobes (E. coli, Salmonella, Shigella) | Ofloxacin |
| Gram-positive bacteria | Ofloxacin |
| Anaerobes (Bacteroides, Clostridium) | Ornidazole |
| Entamoeba histolytica | Ornidazole |
| Giardia lamblia | Ornidazole |
| Trichomonas vaginalis | Ornidazole |
Adverse Effects
| Drug | Key Adverse Effects |
|---|---|
| Ofloxacin | Nausea, headache, dizziness, QTc prolongation, tendinopathy, photosensitivity |
| Ornidazole | Metallic taste, nausea, dizziness, peripheral neuropathy (prolonged use) |
Contraindications & Precautions
- Avoid alcohol during ornidazole therapy (disulfiram-like reaction)
- Avoid in first trimester of pregnancy
- Caution in epilepsy (ornidazole lowers seizure threshold)
- Avoid in children <12 years (fluoroquinolone use is restricted)
- Warfarin interaction: ornidazole potentiates anticoagulant effect
Quick Comparison
| Feature | Cipro + UDCA | Ofloxacin + Ornidazole |
|---|---|---|
| Primary Use | Biliary/hepatic infections | GI, gynecological, protozoal infections |
| Antibiotic | Ciprofloxacin (3rd gen FQ) | Ofloxacin (2nd gen FQ) |
| Partner Drug | Hepatoprotective bile acid | Nitroimidazole antiprotozoal |
| Key Organisms | Biliary gram-negatives | Mixed aerobes + anaerobes + protozoa |
| Alcohol | No restriction (UDCA) | Strict avoidance (ornidazole) |
| Pregnancy | Avoid (FQ) | Avoid 1st trimester |
Clinical note: Both combinations are fixed-dose combination (FDC) tablets widely available in India and South Asian markets. Ofloxacin + Ornidazole (e.g., Oflox-OZ, Zenflox-OZ) is one of the most prescribed FDCs in India for acute diarrheal illness and PID. The Cipro + UDCA combination targets specifically hepatobiliary indications where biliary drug concentration and bile acid metabolism both matter.
This is a shared conversation. Sign in to Orris to start your own chat.